GSA Capital Partners LLP Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

GSA Capital Partners LLP acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 62,326 shares of the biopharmaceutical company's stock, valued at approximately $1,131,000. GSA Capital Partners LLP owned 0.09% of Celldex Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Invesco Ltd. increased its stake in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after acquiring an additional 871 shares during the last quarter. Values First Advisors Inc. grew its holdings in Celldex Therapeutics by 3.2% in the first quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company's stock valued at $550,000 after purchasing an additional 924 shares during the period. MetLife Investment Management LLC grew its holdings in Celldex Therapeutics by 6.1% in the fourth quarter. MetLife Investment Management LLC now owns 39,620 shares of the biopharmaceutical company's stock valued at $1,001,000 after purchasing an additional 2,288 shares during the period. GAMMA Investing LLC increased its position in Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 2,933 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Celldex Therapeutics during the fourth quarter worth approximately $81,000.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. The Goldman Sachs Group lowered their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $50.00 price target on shares of Celldex Therapeutics in a research note on Friday, June 13th. UBS Group reduced their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group began coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 target price for the company. Finally, Morgan Stanley reduced their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $50.11.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX traded up $0.21 during midday trading on Friday, hitting $22.19. The company's stock had a trading volume of 768,053 shares, compared to its average volume of 814,340. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The firm's fifty day moving average price is $21.36 and its 200-day moving average price is $20.80. The firm has a market cap of $1.47 billion, a P/E ratio of -8.22 and a beta of 1.22.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. As a group, research analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.